echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Good news for patients with malignant blood cancer Gamida Cell stem cell transplant product is one step closer to approval

    Good news for patients with malignant blood cancer Gamida Cell stem cell transplant product is one step closer to approval

    • Last Update: 2022-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 9, 2022, Gamida Cell announced that it has initiated rolling submissions to the U.


    According to the press release, omidubicel is expected to be the first advanced cell therapy product approved by the U.


    Omidubicel is an allogeneic hematopoietic stem cell (bone marrow) transplant solution for the treatment of blood cancer patients


    ▲The research and development progress of Omidubicel (Image source: Gamida Cell's official website)

    References:

    [1] Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel.


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.